Table 1.

Baseline patient characteristics (N = 13 131)

Characteristic	No.	%*
Age, years
Median	52
Range	18-80
<40	3067	23
40-49	2648	20
50-64	6042	46
≥65	1374	10
Gender
Male	7562	58
Female	5569	42
Disease
ALL	1726	13
CR1	1023	8
CR2	407	3
CR3	61	0
Relapse/induction failure	235	2
AML	5313	40
Favorable cytogenetics†	224	2
Intermediate/unavailable cytogenetics†	4838	37
Adverse cytogenetics†	251	2
CR1	2800	21
CR2	1014	8
CR3	162	1
Relapse/induction failure	1337	10
CLL	746	6
CR‡	81	1
PR	400	3
Relapse/induction failure	265	2
CML	511	4
Chronic phase 1	274	2
Chronic phase 2	116	1
Accelerated phase	69	1
Blast crisis	52	0
HL	436	3
CR	126	1
PR	225	2
Relapse/induction failure	85	1
MDS	1539	12
Low-risk§	886	7
High-risk§	653	5
Intermediate-risk/unavailable cytogenetics||	1294	10
Adverse cytogenetics||	245	2
Untreated	438	3
CR	177	1
Improved but not CR	448	3
Relapsed/no response/progression	476	4
Multiple myeloma	489	4
CR	78	1
PR	165	1
VGPR	96	1
Relapse/induction failure	150	1
Myeloproliferative neoplasms	426	3
Untreated	197	2
CR	5	0
Improved but not CR	77	1
Relapsed/no response/progression	147	1
NHL¶	1945	15
Indolent B-cell NHL	587	4
CR	183	1
PR	276	2
Relapse/induction failure	128	1
Aggressive B-cell NHL	540	4
CR	181	1
PR	205	2
Relapse/induction failure	154	1
Mantle cell lymphoma	355	3
CR	160	1
PR	149	1
Relapse/induction failure	46	0
T-cell lymphoma	428	3
CR	171	1
PR	164	1
Relapse/induction failure	93	1
BL	35	0
CR	23	0
PR	7	0
Relapse/induction failure	5	0
HCT-CI#
0	5284	40
1-2	3674	28
3+	3975	30
Unavailable	198	2
KPS at HCT
<90	4467	34
90-100	8152	62
Unknown	512	4
Donor match**
MRD	4932	38
Non-MRD	8199	62
Well-matched URD	5020	38
Partially matched URD	1416	11
Mismatched URD	131	1
Mismatched relative	521	4
Matching unknown	83	1
UCB donor	1028	8
Graft source
PB	10508	80
BM	1595	12
UCB	1028	8
Conditioning
MAC	7020	53
Nonmyeloablative/RIC	6111	47
CMV serostatus
Recipient-negative and donor-negative	3245	25
Recipient-negative and donor-positive	1396	11
Recipient-positive and donor-negative	3501	27
Recipient-positive and donor-negative	3702	28
Recipient or donor unknown	1287	10
Gender matching
Male to male	4452	34
Male to female	2967	23
Female to male	2553	19
Female to female	2106	16
Donor gender unknown	1053	8
Year of HCT
Median	2009
Range	2008-2010
Follow-up for survivors, months
Median	24
Range	2-50

BM, bone marrow; CI, conditioning intensity; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MRD, matched related donor; PB, peripheral blood; UCB, umbilical cord blood; URD, unrelated donor; VGPR, very good partial remission.

^*Percentages may not add to 100 because of rounding.

^†Classified according to Armand et al.⁷

^‡Includes 3 cases with untreated disease.

^§Low-risk MDS refers to MDS with ≤5% blasts (refractory anemia with or without ringed sideroblasts and refractory cytopenia with multilineage dysplasia); high-risk MDS refers to MDS with >5% blasts (refractory anemia with excess blasts [RAEB-1 and RAEB-2]).

^||Classified according to Armand et al.⁸

^¶Indolent B-NHL includes follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma. Small lymphocytic lymphoma is included in the CLL group.

^#Classified according to Sorror et al.²

^**Classified according to Weisdorf et al.¹